T cell immunoglobulin and mucin domain-containing protein 3 (TIM3), a member of the TIM
family, was originally identified as a receptor expressed on interferon-γ-producing CD4+ and …

T cell immunoglobulin-3 (Tim-3) was identified nearly 10 years ago as a negative regulator
of IFN-γ-secreting CD4+ T helper 1 and CD8+ T cytotoxic 1 cells. Tim-3 is now classed with …

T-cell immunoglobulin and mucin domain 3 (Tim-3) is a transmembrane protein that in both
mice and humans has been shown to possess various functions in a context-dependent …

Targeting inhibitory immune checkpoint molecules has dramatically changed treatment
paradigms in medical oncology. Understanding the best strategies to unleash a pre-existing …

Immunotherapy is being increasingly recognized as a key therapeutic modality to treat
cancer and represents one of the most exciting treatments for the disease. Fighting cancer …

T cell inhibitory co-receptors play a crucial role in maintaining the balance between
physiologic immune responses and maladaptive ones. T cell immunoglobulin and mucin …

Cancer immunotherapy has produced impressive clinical results in recent years. Despite the
success of the checkpoint blockade strategies targeting cytotoxic T lymphocyte antigen 4 …

T cell immunoglobulin and mucin-containing molecule 3 (TIM-3), first identified as a
molecule expressed on interferon-γ producing T cells, is emerging as an important immune …

Introduction Dysfunction of the immune system is a hallmark of cancer. Through increased
understanding of the complex interactions between immunity and cancer, immunotherapy …

The cancer immunotherapy field has grown exponentially in the past few years, largely
driven by the success of immune checkpoint blockade. Therapies targeting the immune …